Aaron D Schimmer, MD, PhD, FRCPC

Senior Scientist, Princess Margaret Cancer Centre
Director, Research Institute, Princess Margaret Cancer Centre
https://orcid.org/0000-0003-4023-3899
Keywords: translational research, leukemia, caspases, drug discovery, high throughput screening, apoptosis, acute myeloid leukemia (AML)
Our lab is interested in developing new therapeutic strategies for AML (acute myeloid leukemia) that effectively target leukemic stem cells. Using genetic and chemical approaches, including high throughput screens, we identify biological vulnerabilities in the AML cells and stem cells with a focus on mitochondrial and metabolic pathways. Through these efforts, we discover new biological pathways important for the growth and viability of AML and highlight new therapeutic approaches for this disease.
Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.
Sci Transl Med. 2019 Oct 30;11(516):
Sharon D, Cathelin S, Mirali S, Di Trani JM, Yanofsky DJ, Keon KA, Rubinstein JL, Schimmer AD, Ketela T, Chan SM
Global Interactome Mapping of Mitochondrial Intermembrane Space Proteases Identifies a Novel Function for HTRA2.
Proteomics. 2019 Oct 16;:e1900139
Botham A, Coyaud E, Nirmalanandhan VS, Gronda M, Hurren R, Maclean N, St-Germain J, Mirali S, Laurent E, Raught B, Schimmer A
Tafazzin modulates cellular phospholipid composition to regulate AML stemness.
Mol Cell Oncol. 2019;6(5):e1620051
Seneviratne AK, Xu M, Schimmer AD
Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.
Blood Adv. 2019 Aug 13;3(15):2307-2311
Murphy T, Zou J, Daher-Reyes GS, Arruda A, Gupta V, McNamara CJ, Minden MD, Schimmer AD, Sibai H, Yee KWL, Korulla M, Stockley T, Kamel-Reid S, Maze D, Tierens A, Bratman SV, Schuh AC, Chan SM
Phospholipid metabolism regulates AML growth and stemness.
Aging (Albany NY). 2019 Jun 25;11(12):3895-3897
Xu M, Seneviratne AK, Schimmer AD
De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX.
J Med Chem. 2019 Jul 11;62(13):6377-6390
Tan J, Grouleff JJ, Jitkova Y, Diaz DB, Griffith EC, Shao W, Bogdanchikova AF, Poda G, Schimmer AD, Lee RE, Yudin AK
The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids.
Cell Stem Cell. 2019 Jun 06;24(6):1007
Seneviratne AK, Xu M, Aristizabal Henao JJ, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, Mullokandov M, Sharon D, Thomas G, Chouinard-Watkins R, Hawley JR, Schafer C, Yau HL, Khuchua...
17-hydroxy wortmannin restores TRAIL's response by ameliorating increased beclin 1 level and autophagy function in TRAIL-resistant colon cancer cells.
Mol Cancer Ther. 2019 May 15;:
Dai S, Yang S, Hu X, Sun W, Tawa G, Zhu W, Schimmer AD, He C, Fang B, Zhu H, Zheng W
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.
Cancer Cell. 2019 May 13;35(5):721-737.e9
Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD,...
Emotion And Symptom-focused Engagement (EASE): a randomized phase II trial of an integrated psychological and palliative care intervention for patients with acute leukemia.
Support Care Cancer. 2019 Apr 17;:
Rodin G, Malfitano C, Rydall A, Schimmer A, Marmar CM, Mah K, Lo C, Nissim R, Zimmermann C

Pages


 
Senior Scientist, Princess Margaret Cancer Centre
Director, Research Institute, Princess Margaret Cancer Centre

Professor, Department of Medical Biophysics, University of Toronto
Staff Physician, Leukemia Site Group, Princess Margaret Cancer Centre